Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 72162-1610

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 72162-1610). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621610)

This is a description of a transdermal system for administering rivastigmine, a medication used to treat symptoms of dementia. Each patch contains 27 mg of rivastigmine base with a release rate of 13.3 mg over 24 hours. The patches should be stored at room temperature and kept out of reach of children. It is recommended to apply the patch immediately after removing it from the pouch and not to store it unpouched. Instructions on proper usage and disposal can be found by scanning the QR code on the package insert.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

FDA Label Image

Figure 1 (Rivastigmine 02)

FDA Label Image

Figure 2 (Rivastigmine 03)

FDA Label Image

Figure 3 (Rivastigmine 04)

This text seems to provide information about the change in ADAS-Cog rating from baseline during treatment with two different interventions: one involving capsules of 6 mg BID, and the other involving placebo. The data likely shows the least square means, as well as the standard error of the mean (SEM) at different time points, such as at 16 weeks. It also suggests that clinical improvement and decline are being evaluated.*

FDA Label Image

Figure 4 (Rivastigmine 05)

FDA Label Image

Figure 5 (Rivastigmine 06)

This text shows numeric data related to clinical improvement and decline over 52 weeks of treatment with Fivastomine and Tranadermal System. The study measures ADCS-IADL change from baseline using LS means SEM. The dosages used are 3.3 mg/24hr and 9.5 mg/24hr.*

FDA Label Image

Figure 6 (Rivastigmine 07)

This text provides information on a clinical study involving the ADAS-Cog scale and the assessment of cognitive decline over 48 weeks of treatment. The LS means and SEM are used to measure clinical improvement in the study.*

FDA Label Image

Figure 7 (Rivastigmine 08)

FDA Label Image

Figure 8 (Rivastigmine 09)

The text provides data regarding the LS mean change and standard error (STE) for a clinical study comparing two different treatment options over the course of several weeks. The study involves the use of Rivastigmine Transdermal Systems in two different sizes (15cm and 5cm) to assess improvement or decline. The results show significant differences in improvement between the two systems, with p-values provided for statistical significance. The study spanned up to 16 weeks of treatment.*

FDA Label Image

Figure A (Rivastigmine 10)

This text mentions a pouch containing Rivastigmine Transdermal System along with protective liners. It seems to be related to a medical product.*

FDA Label Image

Figure B (Rivastigmine 11)

This text provides a list of body parts where something can be evaluated or located. It includes the left or right upper arm, side of the chest, upper back, and lower back. This information may be used for medical assessments, physical exams, or injury documentation.*

FDA Label Image

Figure C (Rivastigmine 12)

FDA Label Image

Figure D (Rivastigmine 13)

This text mentions protective liners and a sticky surface of a patch possibly indicating the use of protective liners for adhesive patches. These protective liners are likely to serve as a barrier to protect the sticky surface until ready for use.*

FDA Label Image

Figure E (Rivastigmine 14)

FDA Label Image

Figure F (Rivastigmine 15)

FDA Label Image

Figure G (Rivastigmine 16)

FDA Label Image

Figure H (Rivastigmine 17)

This text provides instructions on how to dispose of a slide folded patch by placing it in the trash. It also mentions folding the sticky sides together into an empty pouch and keeping it away from children and pets.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.